PTK2 and familial pancreatic carcinoma: Hence, given the reported expression of PDGFRβ and c-Kit in pancreatic cancer [17], the implication of mast cells in pancreatic cancer development, and association of FAK with chemoresistance, it is hypothesised that masitinib may be of therapeutic potential in this disease.